Skip to main content
. Author manuscript; available in PMC: 2010 Nov 20.
Published in final edited form as: Immunity. 2009 Oct 29;31(5):787–798. doi: 10.1016/j.immuni.2009.09.014

Figure 5. Th17 cells elicit tumor-specific CD8+ T cell responses.

Figure 5

A–B. Dot plots show the frequencies of OVA tetramer-staining (Kb-SIINFEKL) cells in CD45.2+ CD8+ gated T cells obtained from the leukocyte fraction in mice that received either preventive or therapeutic treatment with Th17 cells. Lower graphs represent total number of cells from the average of 4 mice per group. C. Mice were inoculated i.v. with B16-OVA and on day 5 mice received either PBS or 3×106 of Th1 or Th17 OT-II cells i.v. Depleting antibodies against CD8 were administered i.p on day 4 after the tumor inoculation and every 4 days until the endpoint. Shown are the average numbers of tumor colonies present in the lung lobes of each group of mice (n=4, avg. +/− s.d). (**p<0.01, * p<0.05).